Molecular imaging firm Blue Earth Diagnostics presented new results from a phase III trial assessing the diagnostic performance of its Axumin (fluciclovine F-18) PET radiopharmaceutical at the recent Society for Neuro-Oncology scientific meeting in New Orleans.
In the blinded image-evaluation study, lead author Matthew Miller, PhD, and colleagues at Blue Earth examined the PET and MRI datasets of 35 patients who received fluciclovine F-18. They found that fluciclovine F-18 PET with MRI had a sensitivity exceeding that of MRI alone for the diagnosis of glioma, though it was not as high as the sensitivity of MRI with a fluid-attenuated inversion-recovery (FLAIR) protocol.
Furthermore, fluciclovine F-18 PET with MRI had a positive predictive value of more than 90% and revealed additional gliomas that were not identified on MRI alone.
